Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04849312 · ClinicalTrials.gov registry record
Prediction of 30-Day Readmission Using Machine Learning
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 372
- Enrollment target
NCT04849312: Completed study, sponsored by Brigham and Women's Hospital.
NCT04849312 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 372 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04849312 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 372 participants
- Enrollment target
Study Summary
This is a retrospective observational study drawing on data from the Brigham and Women's Home Hospital database. Sociodemographic and clinic data from a training cohort were used to train a machine learning algorithm to predict the likelihood of 30-day readmission throughout a patient's admission. This algorithm was then validated in a validation cohort.
Primary Outcome
Unplanned hospital admission within 30 days of having been discharged
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2019-11-30 |
What the finished NCT04849312 record still lists
NCT04849312 is an observational study that tracks outcomes without assigning an intervention. The registered 372 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04849312 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04849312 about?
NCT04849312 is a clinical study titled "Prediction of 30-Day Readmission Using Machine Learning". This is a retrospective observational study drawing on data from the Brigham and Women's Home Hospital database. Sociodemographic and clinic data from a training cohort were used to train a machine learning algorithm to predict the likelihood of 30-day readmission throughout a patient's admission. T...
What is the current status of trial NCT04849312?
This trial is currently completed. The enrollment target is 372 participants. The study started on 2017-06-01. Estimated completion is 2019-11-30.
Who is sponsoring clinical trial NCT04849312?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- NCT05318105 · 372 participants · NA
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
- NCT06797635 · 372 participants · Phase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI